Literature DB >> 24272022

Diagnostic accuracy of laparoscopy following computed tomography (CT) scanning for assessing the resectability with curative intent in pancreatic and periampullary cancer.

Victoria B Allen1, Kurinchi Selvan Gurusamy, Yemisi Takwoingi, Amun Kalia, Brian R Davidson.   

Abstract

BACKGROUND: Surgical resection is the only potentially curative treatment for pancreatic and periampullary cancer. A considerable proportion of patients undergo unnecessary laparotomy because of underestimation of the extent of the cancer on computed tomography (CT) scanning. Laparoscopy can detect metastases not visualised on CT scanning, enabling better assessment of the spread of cancer (staging of cancer). There has been no systematic review or meta-analysis assessing the role of diagnostic laparoscopy in assessing the resectability with curative intent in patients with pancreatic and periampullary cancer.
OBJECTIVES: To determine the diagnostic accuracy of diagnostic laparoscopy performed as an add-on test to CT scanning in the assessment of curative resectability in pancreatic and periampullary cancer. SEARCH
METHODS: We searched the Cochrane Register of Diagnostic Test Accuracy Studies, the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE via PubMed, EMBASE via OvidSP (from inception to 13 September 2012), and Science Citation Index Expanded (from 1980 to 13 September 2012). SELECTION CRITERIA: We included diagnostic accuracy studies of diagnostic laparoscopy in patients with potentially resectable pancreatic and periampullary cancer on CT scan, where confirmation of liver or peritoneal involvement was by histopathological examination of suspicious (liver or peritoneal) lesions obtained at diagnostic laparoscopy or laparotomy. We accepted any criteria of resectability used in the studies. We included studies irrespective of language, publication status, or study design (prospective or retrospective). We excluded case-control studies. DATA COLLECTION AND ANALYSIS: Two authors independently performed data extraction and quality assessment using the QUADAS-2 tool. The specificity of diagnostic laparoscopy in all studies was 1 because there were no false positives since laparoscopy and the reference standard are one and the same if histological examination after diagnostic laparoscopy is positive. Therefore, the sensitivities were meta-analysed using a univariate random-effects logistic regression model. The probability of unresectability in patients who had a negative laparoscopy (post-test probability for patients with a negative test result) was calculated using the median probability of unresectability (pre-test probability) from the included studies and the negative likelihood ratio derived from the model (specificity of 1 assumed). The difference between the pre-test and post-test probabilities gave the overall added value of diagnostic laparoscopy compared to the standard practice of CT scan staging alone. MAIN
RESULTS: Fifteen studies with a total of 1015 patients were included in the meta-analysis. Only one study including 52 patients had a low risk of bias and low applicability concern in the patient selection domain. The median pre-test probability of unresectable disease after CT scanning across studies was 40.3% (that is 40 out of 100 patients who had resectable cancer after CT scan were found to have unresectable disease on laparotomy). The summary sensitivity of diagnostic laparoscopy was 68.7% (95% CI 54.3% to 80.2%). Assuming a pre-test probability of 40.3%, the post-test probability of unresectable disease for patients with a negative test result was 0.17 (95% CI 0.12 to 0.24). This indicates that if a patient is said to have resectable disease after diagnostic laparoscopy and CT scan, there is a 17% probability that their cancer will be unresectable compared to a 40% probability for those receiving CT alone.A subgroup analysis of patients with pancreatic cancer gave a summary sensitivity of 67.9% (95% CI 41.1% to 86.5%). The post-test probability of unresectable disease after being considered resectable on both CT and diagnostic laparoscopy was 18% compared to 40% for those receiving CT alone. AUTHORS'
CONCLUSIONS: Diagnostic laparoscopy may decrease the rate of unnecessary laparotomy in patients with pancreatic and periampullary cancer found to have resectable disease on CT scan. On average, using diagnostic laparoscopy with biopsy and histopathological confirmation of suspicious lesions prior to laparotomy would avoid 23 unnecessary laparotomies in 100 patients in whom resection of cancer with curative intent is planned.

Entities:  

Mesh:

Year:  2013        PMID: 24272022     DOI: 10.1002/14651858.CD009323.pub2

Source DB:  PubMed          Journal:  Cochrane Database Syst Rev        ISSN: 1361-6137


  16 in total

Review 1.  Adjuvant and neoadjuvant therapies in resectable pancreatic cancer: a systematic review of randomized controlled trials.

Authors:  Francesco A D'Angelo; Laura Antolino; Mara La Rocca; Niccolò Petrucciani; Paolo Magistri; Paolo Aurello; Giovanni Ramacciato
Journal:  Med Oncol       Date:  2016-02-17       Impact factor: 3.064

Review 2.  Minireview on laparoscopic hepatobiliary and pancreatic surgery.

Authors:  Clara Tan-Tam; Stephen W Chung
Journal:  World J Gastrointest Endosc       Date:  2014-03-16

3.  Diagnostic Laparoscopy Prior to Neoadjuvant Therapy in Pancreatic Cancer Is High Yield: an Analysis of Outcomes and Costs.

Authors:  June S Peng; Jeffrey Mino; Rosebel Monteiro; Gareth Morris-Stiff; Noaman S Ali; Jane Wey; Kevin M El-Hayek; R Matthew Walsh; Sricharan Chalikonda
Journal:  J Gastrointest Surg       Date:  2017-06-08       Impact factor: 3.452

4.  Impact of the time interval between MDCT imaging and surgery on the accuracy of identifying metastatic disease in patients with pancreatic cancer.

Authors:  Siva P Raman; Sushanth Reddy; Matthew J Weiss; Lindsey L Manos; John L Cameron; Lei Zheng; Joseph M Herman; Ralph H Hruban; Elliot K Fishman; Christopher L Wolfgang
Journal:  AJR Am J Roentgenol       Date:  2015-01       Impact factor: 3.959

5.  Radiologically occult metastatic pancreatic cancer: how can we avoid unbeneficial resection?

Authors:  Atsushi Oba; Yosuke Inoue; Yoshihiro Ono; Shoichi Irie; Takafumi Sato; Yoshihiro Mise; Hiromichi Ito; Yu Takahashi; Akio Saiura
Journal:  Langenbecks Arch Surg       Date:  2019-11-28       Impact factor: 3.445

6.  Cathepsin S-cleavable, multi-block HPMA copolymers for improved SPECT/CT imaging of pancreatic cancer.

Authors:  Wei Fan; Wen Shi; Wenting Zhang; Yinnong Jia; Zhengyuan Zhou; Susan K Brusnahan; Jered C Garrison
Journal:  Biomaterials       Date:  2016-06-08       Impact factor: 12.479

Review 7.  Diagnostic accuracy of laparoscopy following computed tomography (CT) scanning for assessing the resectability with curative intent in pancreatic and periampullary cancer.

Authors:  Victoria B Allen; Kurinchi Selvan Gurusamy; Yemisi Takwoingi; Amun Kalia; Brian R Davidson
Journal:  Cochrane Database Syst Rev       Date:  2016-07-06

8.  Predicting positive peritoneal cytology in pancreatic cancer.

Authors:  Eileen A O'Halloran; Tamsin Board; Max Lefton; Karthik Devarajan; Efrat Dotan; Joshua Meyer; Sanjay S Reddy
Journal:  J Cancer Res Clin Oncol       Date:  2021-01-03       Impact factor: 4.322

9.  Cost-effectiveness of diagnostic laparoscopy for assessing resectability in pancreatic and periampullary cancer.

Authors:  Stephen Morris; Kurinchi S Gurusamy; Jessica Sheringham; Brian R Davidson
Journal:  BMC Gastroenterol       Date:  2015-04-02       Impact factor: 3.067

Review 10.  Blood CEA levels for detecting recurrent colorectal cancer.

Authors:  Brian D Nicholson; Bethany Shinkins; Indika Pathiraja; Nia W Roberts; Tim J James; Susan Mallett; Rafael Perera; John N Primrose; David Mant
Journal:  Cochrane Database Syst Rev       Date:  2015-12-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.